We served as lead counsel representing the former owners of a multi-state retail pharmacy chain in connection with a Department of Justice (DOJ) investigation regarding alleged violations of the False Claims Act (FCA) resulting from inaccurate reporting of usual and customary pricing of generic drugs. The case resulted in declination by DOJ and dismissal of the underlying qui tam lawsuit after the filing of a motion to dismiss under the FCA’s first-to-file rule. Reported case: U.S. ex rel. Phillis v. Stephen L. LaFrance Holdings, 2018 WL 4839057 (N.D. Okla. Oct. 4, 2018).
Representation of Retail Pharmacy Owners: U.S. ex rel. Phillips v. Stephen L. LaFrance Holdings, Inc. (N.D. Okla.)
You Also May Be Interested In:
Successfully represented a private equity backed portfolio provider and its management company in a voluntary disclosure to HHS-OIG involving improper billing
Lead counsel for a large long-term care company named as a defendant in a FCA qui tam action involving allegations of medically unnecessary services and improper billing
Represented a large hospital system and negotiated a favorable settlement with HHS-OIG utilizing the OIG’s Self-Disclosure Protocol. More specifically, our team conducted an internal investigation into possible compliance issues, drafted the disclosure for provision to HHS-OIG, and negotiated the final settlement between the parties resulting in a favorable resolution for the hospital.